Drug · CHEMBL2
PRAZOSIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PRAZOSIN. Drugs and targets, record CHEMBL2. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL2
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/148 |
| ADRA1B | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/147 |
| ADRA1D | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | https://conductscience.org/library/genes/146 |
Source ChEMBL
Diseases24
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 24Source Open Targets
See all 24 diseasesTrials57
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02655354 | A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity | 635 | 2021-07-02 | prazosin | Its name | ClinicalTrials.gov | |
| NCT00532493 | Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD | Phase 3 | 304 | 2014-06-18 | prazosin | Its name | ClinicalTrials.gov |
| NCT01923129 | Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery | 142 | 2019-02-20 | prazosin | Its name | ClinicalTrials.gov | |
| NCT01542372 | Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD | Phase 4 | 114 | 2017-05-17 | prazosin | Its name | ClinicalTrials.gov |
| NCT00585780 | Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse | Phase 1/2 | 100 | 2020-07-27 | prazosin | Its name | ClinicalTrials.gov |
| NCT00744055 | Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD). | Phase 3 | 96 | 2016-01-18 | prazosin | Its name | ClinicalTrials.gov |
| NCT00762710 | Study of the Medication Prazosin for Alcohol Dependence | Phase 2 | 92 | 2020-06-04 | prazosin | Its name | ClinicalTrials.gov |
| NCT02965027 | Prazosin for Post-Concussive Headaches | Phase 4 | 89 | 2024-07-10 | prazosin | Its name | ClinicalTrials.gov |
| NCT02966340 | Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment | Phase 1/2 | 70 | 2019-05-28 | prazosin | Its name | ClinicalTrials.gov |
| NCT00202449 | Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance | 59 | 2012-07-12 | prazosin | Its name | ClinicalTrials.gov |
1 to 10 of 57
See all 57 trialsComparisons in its trials41
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intervention vs Usual Care: deaths from any cause | 6 of 265 | 3 of 370 | 635 | NCT02655354 | Trial comparisons |
| Intervention vs Usual Care: serious adverse events | 15 of 265 | 13 of 370 | 635 | NCT02655354 | Trial comparisons |
| Prazosin Group vs Placebo Group: serious adverse events | 18 of 152 | 17 of 152 | 304 | NCT00532493 | Trial comparisons |
| 24 Hour Postop Catheter Removal vs 72 Hour Postoperative Catheter Removal: Number of Participants With Acute Urinary Retention | 6 of 71 | 7 of 71 | 142 | NCT01923129 | Trial comparisons |
| 24 Hour Postop Catheter Removal vs 72 Hour Postoperative Catheter Removal: deaths from any cause | 0 of 71 | 0 of 71 | 142 | NCT01923129 | Trial comparisons |
| 24 Hour Postop Catheter Removal vs 72 Hour Postoperative Catheter Removal: Number of Participants With a Symptomatic Urinary Tract Infection | 0 of 71 | 8 of 71 | 142 | NCT01923129 | Trial comparisons |
| 24 Hour Postop Catheter Removal vs 72 Hour Postoperative Catheter Removal: serious adverse events | 0 of 71 | 0 of 71 | 142 | NCT01923129 | Trial comparisons |
| Prazosin 2mg Trials vs Placebo Trials: deaths from any cause | 0 of 64 | 0 of 64 | 128 | NCT02966340 | Trial comparisons |
| Prazosin 2mg Trials vs Placebo Trials: serious adverse events | 0 of 64 | 0 of 64 | 128 | NCT02966340 | Trial comparisons |
| Prazosin vs Placebo: serious adverse events | 0 of 50 | 0 of 46 | 96 | NCT00744055 | Trial comparisons |
1 to 10 of 41
See all 41 comparisons in its trialsPapers from its trials27
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Rapid Visual Information Processing | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL2
GET https://conductscience.org/api/drugs/v1/CHEMBL2/diseases?page=2